Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells

SRC: A Century of Science Brought to the Clinic

(2015) Alexey Aleshin et al.   NEOPLASIA

Docetaxel-based combination therapy for castration-resistant prostate cancer

(2010) M. D. Galsky et al.   ANNALS OF ONCOLOGY

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Targeting SRC in glioblastoma tumors and brain metastases: Rationale and preclinical studies

(2010) Manmeet S. Ahluwalia et al.   CANCER LETTERS

New molecular targets in bone metastases

(2010) D. Santini et al.   CANCER TREATMENT REVIEWS

Dasatinib: A potent SRC inhibitor in clinical development for the treatment of solid tumors

(2010) John Araujo et al.   CANCER TREATMENT REVIEWS

Antitumor Activity of Targeting Src Kinases in Endothelial and Myeloid Cell Compartments of the Tumor Microenvironment

(2010) W. Liang et al.   CLINICAL CANCER RESEARCH

Targeting the Tumor Microenvironment With Src Kinase Inhibition

(2010) A. S. Chung et al.   CLINICAL CANCER RESEARCH

Distinct Interactions Between c-Src and c-Met in Mediating Resistance to c-Src Inhibition in Head and Neck Cancer

(2010) B. Sen et al.   CLINICAL CANCER RESEARCH

Advances in Targeting Src in the Treatment of Breast Cancer and Other Solid Malignancies

(2010) E. L. Mayer et al.   CLINICAL CANCER RESEARCH

Cancer metastasis as a therapeutic target

(2010) Jonathan Sleeman et al.   EUROPEAN JOURNAL OF CANCER

Dasatinib reduces FAK phosphorylation increasing the effects of RPI-1 inhibition in a RET/PTC1-expressing cell line

(2010) Dario Caccia et al.   Molecular Cancer

BMS-777607, a Small-Molecule Met Kinase Inhibitor, Suppresses Hepatocyte Growth Factor-Stimulated Prostate Cancer Metastatic Phenotype In vitro

(2010) Y. Dai et al.   MOLECULAR CANCER THERAPEUTICS

Targeted Inhibition of Src Kinase Signaling Attenuates Pancreatic Tumorigenesis

(2010) Nagathihalli S. Nagaraj et al.   MOLECULAR CANCER THERAPEUTICS

Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis

(2009) T Koreckij et al.   BRITISH JOURNAL OF CANCER

Activity of the multikinase inhibitor dasatinib against ovarian cancer cells

(2009) G E Konecny et al.   BRITISH JOURNAL OF CANCER

SRC kinase inhibition: Targeting bone metastases and tumor growth in prostate and breast cancer

(2009) Fred Saad et al.   CANCER TREATMENT REVIEWS

Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer

(2009) E. Y. Yu et al.   CLINICAL CANCER RESEARCH

Src Family Kinase Activity Is Up-Regulated in Hormone-Refractory Prostate Cancer

(2009) O. Tatarov et al.   CLINICAL CANCER RESEARCH

Src kinases as therapeutic targets for cancer

(2009) Lori C. Kim et al.   Nature Reviews Clinical Oncology

Targeting Src Family Kinases Inhibits Growth and Lymph Node Metastases of Prostate Cancer in an Orthotopic Nude Mouse Model

(2008) S. I. Park et al.   CANCER RESEARCH

Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines

(2008) Alex J Eustace et al.   Journal of Translational Medicine

Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in bone

(2008) A. Yano et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA